Enrollment Completed for Phase 3 Trial Testing Provenge in Prostate Cancer Patients on Active Surveillance
News
Dendreon Pharmaceuticals has completed patient enrollment ahead of schedule in an ongoing Phase 3 trial assessing the safety and efficacy of its immunotherapy Provenge (sipuleucel-T) for men with early-stage prostate ... Read more